PE20090210A1 - Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa - Google Patents

Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa

Info

Publication number
PE20090210A1
PE20090210A1 PE2008000710A PE2008000710A PE20090210A1 PE 20090210 A1 PE20090210 A1 PE 20090210A1 PE 2008000710 A PE2008000710 A PE 2008000710A PE 2008000710 A PE2008000710 A PE 2008000710A PE 20090210 A1 PE20090210 A1 PE 20090210A1
Authority
PE
Peru
Prior art keywords
alkyl
carbocyclyl
jak
pyrimidin
fluoro
Prior art date
Application number
PE2008000710A
Other languages
English (en)
Inventor
Huiping Guan
Barry Raymond Hayter
Shan Huang
Stephanos Ioannidis
Jeffrey Johannes
Michelle Lamb
Bo Peng
Bin Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090210A1 publication Critical patent/PE20090210A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I, DONDE; EL ANILLO A ES FENILO Y HETEROCICLILO DE 6 MIEMBROS; X ES -NH-, -O-, -S-; R1 ES H, -CN, (C1-C6)ALQUILO, CARBOCICLILO DE 3 A 5 MIEMBROS, -N(R1a)C(O)R1b, ENTRE OTROS; R1a ES (C1-C6)ALQUILO, CARBOCICLILO DE 3 A 5 MIEMBROS, ENTRE OTROS; R1b ES (C2-C6)ALQUENILO, HETEROCICLILO DE 5 MIEMBROS, (C1-C6)ALQUILO, ENTRE OTROS; R2 ES HALO, (C2-C6)ALQUENILO, -OC(O)N(R2a)2, ENTRE OTROS; R2a ES H, (C1-C6)ALQUILO, CARBOCICLILO, ENTRE OTROS; R2 ES-CN, -OR2a, -N(R2a)N(R2a)2, ENTRE OTROS; R3 ES HALO, (C1-C6)ALQUILO, C(R3a)=N(OR3a), ENTRE OTROS; R3a ES H, (C1-C6)ALQUILO, CARBOCICLILO, ENTRE OTROS; R4 ES (C1-C6)ALQUILO, -NO2, -N(R4a)C(O)N(R4a)2; R4a ES (C1-C6)ALQUILO, CARBOCICLILO, H, ENTRE OTROS. SON SELECCIONADOS 5-FLUORO-N4-[(S)-1-(5-FLUORO-PIRIMIDIN-2-IL)-ETIL]-N2-(5-METOXI-1H-PIRAZOL-3-IL)-6-MORFOLIN-4-IL-PIRIMIDIN-2,4-DIAMINA, 1-(5-FLUORO-6-(1-(5-FLUOROPIRIMIDIN-2-IL)ETOXI)-2-(5-METIL-1H-PIRAZOL-3-ILAMINO)PIRIMIDIN-4-IL)PIPERIDIN-4-CARBONITRILO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION Y COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD INHIBIDORA JAK QUINASA Y SON UTILES EN EL TRATAMIENTO DE DESORDENES MIELOPROLIFERATIVOS Y CANCER
PE2008000710A 2007-04-25 2008-04-25 Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa PE20090210A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91401707P 2007-04-25 2007-04-25

Publications (1)

Publication Number Publication Date
PE20090210A1 true PE20090210A1 (es) 2009-04-01

Family

ID=39618922

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000710A PE20090210A1 (es) 2007-04-25 2008-04-25 Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa

Country Status (5)

Country Link
AR (1) AR066147A1 (es)
PE (1) PE20090210A1 (es)
TW (1) TW200846344A (es)
UY (1) UY31048A1 (es)
WO (1) WO2008132502A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2576541T3 (pl) 2010-06-04 2016-10-31 Pochodne aminopirymidyny jako modulatory lrrk2
PL2638031T3 (pl) 2010-11-10 2018-03-30 Genentech, Inc. Pirazolowo-aminopirymidynowe pochodne jako modulatory LRRK2
ITMI20110472A1 (it) * 2011-03-24 2012-09-25 Erregierre Spa Procedimento per la preparazione di zileuton ad elevata purezza
JP2014521623A (ja) * 2011-07-28 2014-08-28 セルゾーム リミティッド Jak阻害剤としてのヘテロシクリルピリミジンアナログ
EP2554544A1 (en) * 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2758389B1 (en) * 2011-09-22 2017-06-07 Merck Sharp & Dohme Corp. Pyrazole carboxamides as janus kinase inhibitors
JP6197031B2 (ja) * 2012-05-24 2017-09-13 セルゾーム リミティッド Tyk2阻害剤としてのヘテロシクリルピリミジン類似体
KR102455889B1 (ko) 2012-11-21 2022-10-17 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 bmi-1 저해제
CN105683166B (zh) 2013-08-30 2020-06-16 Ptc医疗公司 取代的嘧啶Bmi-1抑制剂
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CN105254613A (zh) * 2015-10-08 2016-01-20 苏州云轩医药科技有限公司 具有Wnt信号通路抑制活性的杂环化合物及其应用
KR20180061363A (ko) 2015-10-08 2018-06-07 쑤저우 운씨엔 이야오 커지 요씨엔 공시 Wnt 신호 전달 경로 억제제 및 이의 치료적 적용
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
CA3104521A1 (en) 2018-07-05 2020-01-09 Mayo Foundation For Medical Education And Research Pikfyve inhibitors
CN113164479A (zh) 2018-08-17 2021-07-23 Ptc医疗公司 用于治疗胰腺癌的方法
CN111454214B (zh) * 2020-05-27 2023-04-07 龙曦宁(上海)医药科技有限公司 一种2-甲氧基1-嘧啶乙胺盐酸盐的合成方法
EP4363058A1 (en) * 2021-07-01 2024-05-08 Aerie Pharmaceuticals, Inc. Azetidinyl pyrimidines and uses thereof
WO2024006916A1 (en) * 2022-06-29 2024-01-04 Aerie Pharmaceuticals, Inc. Azetidinyl pyrimidines and uses thereof as jak inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
JP2008540391A (ja) * 2005-05-05 2008-11-20 アストラゼネカ アクチボラグ ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors

Also Published As

Publication number Publication date
AR066147A1 (es) 2009-07-29
WO2008132502A1 (en) 2008-11-06
TW200846344A (en) 2008-12-01
UY31048A1 (es) 2008-11-28

Similar Documents

Publication Publication Date Title
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
PE20061067A1 (es) Derivados de pirimidina
PE20142340A1 (es) Inhibidores de bromodominios
PA8632701A1 (es) Compuestos terapeuticos
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20080527A1 (es) Derivado de pirimidina como inhibidor de la fosfatidilinositol 3-quinasa (pi3k)
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
PE20091577A1 (es) Inhibidores de cinasa pim y metodos para su uso
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
PE20150636A1 (es) Dicianopiridinas alquilamino-sustituidas y sus profarmacos de ester de aminoacido
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
NZ702571A (en) 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
PE20110222A1 (es) Inhibidores de dipeptidilpeptidasa iv
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
MX2007013624A (es) Inhibidores de proteina cinasa.
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
MX344669B (es) Agente antiplaquetas novedoso.
PE20080074A1 (es) Derivados de amida como agentes inhibidores de la quinasa c-fms
UY29246A1 (es) Nuevos compuestos
PE20090773A1 (es) Derivados de morfolina pirimidina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal